221 related articles for article (PubMed ID: 23070762)
1. Anti-PEG IgM production via a PEGylated nano-carrier system for nucleic acid delivery.
Ichihara M; Moriyoshi N; Lila AS; Ishida T; Kiwada H
Methods Mol Biol; 2013; 948():35-47. PubMed ID: 23070762
[TBL] [Abstract][Full Text] [Related]
2. Anti-PEG IgM Production via a PEGylated Nanocarrier System for Nucleic Acid Delivery.
Abu Lila AS; Ishida T
Methods Mol Biol; 2019; 1943():333-346. PubMed ID: 30838627
[TBL] [Abstract][Full Text] [Related]
3. Application of polyglycerol coating to plasmid DNA lipoplex for the evasion of the accelerated blood clearance phenomenon in nucleic acid delivery.
Abu Lila AS; Uehara Y; Ishida T; Kiwada H
J Pharm Sci; 2014 Feb; 103(2):557-66. PubMed ID: 24347396
[TBL] [Abstract][Full Text] [Related]
4. CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes.
Tagami T; Nakamura K; Shimizu T; Yamazaki N; Ishida T; Kiwada H
J Control Release; 2010 Mar; 142(2):160-6. PubMed ID: 19850094
[TBL] [Abstract][Full Text] [Related]
5. Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production.
Tagami T; Nakamura K; Shimizu T; Ishida T; Kiwada H
J Control Release; 2009 Aug; 137(3):234-40. PubMed ID: 19361546
[TBL] [Abstract][Full Text] [Related]
6. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes.
Wang X; Ishida T; Kiwada H
J Control Release; 2007 Jun; 119(2):236-44. PubMed ID: 17399838
[TBL] [Abstract][Full Text] [Related]
7. Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA.
Tagami T; Uehara Y; Moriyoshi N; Ishida T; Kiwada H
J Control Release; 2011 Apr; 151(2):149-54. PubMed ID: 21223988
[TBL] [Abstract][Full Text] [Related]
8. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.
Abu Lila AS; Nawata K; Shimizu T; Ishida T; Kiwada H
Int J Pharm; 2013 Nov; 456(1):235-42. PubMed ID: 23928149
[TBL] [Abstract][Full Text] [Related]
9. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes.
Ishida T; Kiwada H
Int J Pharm; 2008 Apr; 354(1-2):56-62. PubMed ID: 18083313
[TBL] [Abstract][Full Text] [Related]
10. B cell-intrinsic toll-like receptor 7 is responsible for the enhanced anti-PEG IgM production following injection of siRNA-containing PEGylated lipoplex in mice.
Hashimoto Y; Abu Lila AS; Shimizu T; Ishida T; Kiwada H
J Control Release; 2014 Jun; 184():1-8. PubMed ID: 24727075
[TBL] [Abstract][Full Text] [Related]
11. Hydrophobic blocks of PEG-conjugates play a significant role in the accelerated blood clearance (ABC) phenomenon.
Shiraishi K; Hamano M; Ma H; Kawano K; Maitani Y; Aoshi T; Ishii KJ; Yokoyama M
J Control Release; 2013 Feb; 165(3):183-90. PubMed ID: 23220106
[TBL] [Abstract][Full Text] [Related]
12. Anti-PEG IgM Is a Major Contributor to the Accelerated Blood Clearance of Polyethylene Glycol-Conjugated Protein.
Mima Y; Hashimoto Y; Shimizu T; Kiwada H; Ishida T
Mol Pharm; 2015 Jul; 12(7):2429-35. PubMed ID: 26070445
[TBL] [Abstract][Full Text] [Related]
13. Relationship between the concentration of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes in mice.
Hashimoto Y; Shimizu T; Abu Lila AS; Ishida T; Kiwada H
Biol Pharm Bull; 2015; 38(3):417-24. PubMed ID: 25757923
[TBL] [Abstract][Full Text] [Related]
14. Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon.
Shimizu T; Ishida T; Kiwada H
Immunobiology; 2013 May; 218(5):725-32. PubMed ID: 22995937
[TBL] [Abstract][Full Text] [Related]
15. A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes.
Shimizu T; Abu Lila AS; Fujita R; Awata M; Kawanishi M; Hashimoto Y; Okuhira K; Ishima Y; Ishida T
Eur J Pharm Biopharm; 2018 Jun; 127():142-149. PubMed ID: 29462689
[TBL] [Abstract][Full Text] [Related]
16. Prolongation of time interval between doses could eliminate accelerated blood clearance phenomenon induced by pegylated liposomal topotecan.
Li C; Zhao X; Wang Y; Yang H; Li H; Li H; Tian W; Yang J; Cui J
Int J Pharm; 2013 Feb; 443(1-2):17-25. PubMed ID: 23318366
[TBL] [Abstract][Full Text] [Related]
17. Hemoglobin vesicles, polyethylene glycol (PEG)ylated liposomes developed as a red blood cell substitute, do not induce the accelerated blood clearance phenomenon in mice.
Taguchi K; Urata Y; Anraku M; Watanabe H; Kadowaki D; Sakai H; Horinouchi H; Kobayashi K; Tsuchida E; Maruyama T; Otagiri M
Drug Metab Dispos; 2009 Nov; 37(11):2197-203. PubMed ID: 19679674
[TBL] [Abstract][Full Text] [Related]
18. Ex-vivo/in-vitro anti-polyethylene glycol (PEG) immunoglobulin M production from murine splenic B cells stimulated by PEGylated liposome.
Abu Lila AS; Ichihara M; Shimizu T; Ishida T; Kiwada H
Biol Pharm Bull; 2013; 36(11):1842-8. PubMed ID: 24189428
[TBL] [Abstract][Full Text] [Related]
19. T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes.
Koide H; Asai T; Hatanaka K; Akai S; Ishii T; Kenjo E; Ishida T; Kiwada H; Tsukada H; Oku N
Int J Pharm; 2010 Jun; 392(1-2):218-23. PubMed ID: 20227473
[TBL] [Abstract][Full Text] [Related]
20. Zwitterionic poly(carboxybetaine)-based cationic liposomes for effective delivery of small interfering RNA therapeutics without accelerated blood clearance phenomenon.
Li Y; Liu R; Shi Y; Zhang Z; Zhang X
Theranostics; 2015; 5(6):583-96. PubMed ID: 25825598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
